Pages
- Adoptive T-cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis
- Terms of Use
- Expanded Access
- Clinical Studies
- Multiple Sclerosis
- PTLD
- About EBV
- Patients & Families
- Contact
- Stories of Strength
- Careers
- PO Terms and Conditions
- Suppliers
- Job Search
- Independent Medical Education
- Expanded Access
- Clinical Studies
- Job Categories
- Medical Professionals
- Pipeline
- Technology
- Privacy Policy
- About Us
- Atara Biotherapeutics
MS Stories
PTLD Stories
Publications
- Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy Without Gene Editing
- ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors
- ATA3219: A Potent Next Generation Allogeneic Off the Shelf CD19 CAR T Therapy Without the Need for Gene Editing
- ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors
- Regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-intrinsic PD1 blockade: Translation to a phase I trial
- Phase 1 Study of the Safety and Efficacy of ATA188, an Off-the-shelf, Allogeneic Epstein-Barr Virus-targeted T-cell Immunotherapy to Treat Progressive Forms of Multiple Sclerosis
- Functional Demonstration of CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T Cells: An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform